These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24491303)

  • 1. KRAS and cancer stem cells in APC-mutant colorectal cancer.
    Fearon ER; Wicha MS
    J Natl Cancer Inst; 2014 Feb; 106(2):djt444. PubMed ID: 24491303
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Cristóbal I; Rincón R; Manso R; Rojo F; García-Foncillas J
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136032
    [No Abstract]   [Full Text] [Related]  

  • 3. Response.
    Moon BS; Cho YH; Jeong WJ; Choi KY
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136033
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
    J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
    Lee SK; Hwang JH; Choi KY
    Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
    Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
    Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India.
    Raman R; Kotapalli V; Adduri R; Gowrishankar S; Bashyam L; Chaudhary A; Vamsy M; Patnaik S; Srinivasulu M; Sastry R; Rao S; Vasala A; Kalidindi N; Pollack J; Murthy S; Bashyam M
    Mol Carcinog; 2014 Feb; 53 Suppl 1(0 1):E181-6. PubMed ID: 23168910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
    Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
    Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.
    Obrador-Hevia A; Chin SF; González S; Rees J; Vilardell F; Greenson JK; Cordero D; Moreno V; Caldas C; Capellá G
    J Pathol; 2010 May; 221(1):57-67. PubMed ID: 20196079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Setting future standards for KRAS testing in colorectal cancer.
    van Krieken H; Tol J
    Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
    [No Abstract]   [Full Text] [Related]  

  • 11. Wnt and Kras signaling-dark siblings in lung cancer.
    Pacheco-Pinedo EC; Morrisey EE
    Oncotarget; 2011 Jul; 2(7):569-74. PubMed ID: 21753228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutations in primary and metastatic colorectal cancer.
    Han CB; Li F; Ma JT; Zou HW
    Int J Colorectal Dis; 2013 May; 28(5):731-2. PubMed ID: 22744738
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
    Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
    Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
    [No Abstract]   [Full Text] [Related]  

  • 14. Stromal cells do not share KRAS mutations that the epithelial component harbors in colorectal carcinomas.
    Baloglu H; Yigit N
    Cancer Lett; 2011 Sep; 308(1):118-21. PubMed ID: 21624768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
    Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
    Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Stem cell theory of colorectal cancer and its connection with molecular-biological data].
    Hagymási K; Molnár B; Sipos F; Galamb O; Tulassay Z
    Orv Hetil; 2007 Apr; 148(17):779-85. PubMed ID: 17452307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β.
    Lee SK; Jeong WJ; Cho YH; Cha PH; Yoon JS; Ro EJ; Choi S; Oh JM; Heo Y; Kim H; Min DS; Han G; Lee W; Choi KY
    EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30413483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
    Bass A
    J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
    Kawamoto Y; Yoshino T
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
    [No Abstract]   [Full Text] [Related]  

  • 20. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.